Cas:4017-32-7 ethyl 6-chloro-3-oxo-4H-quinoxaline-2-carboxylate manufacturer & supplier

Chemical Name:ethyl 6-chloro-3-oxo-4H-quinoxaline-2-carboxylate

CAS.NO:4017-32-7

Synonyms:6-Chlor-3-hydroxy-chinoxalin-2-carbonsaeure-ethylester;2-Quinoxalinecarboxylicacid,6-chloro-3,4-dihydro-3-oxo-,ethyl ester;6-chloro-3,4-dihydro-3-oxo-2-quinoxalinecarboxylic acid,ethyl ester;ETHYL 6-CHLORO-3-OXO-3,4-DIHYDROQUINOXALINE-2-CARBOXYLATE;6-chloro-3-oxo-3,4-dihydro-quinoxaline-2-carboxylic acid ethyl ester;ethyl 6-Chloro-3,4-dihydro-3-oxoquinoxaline-2-carboxylate

Molecular Formula:C₁₁H₉ClN₂O₃

Molecular Weight:252.65400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:72.05000

Exact Mass:252.03000

LogP:1.75320

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-Chlor-3-hydroxy-chinoxalin-2-carbonsaeure-ethylester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 6-Chloro-3,4-dihydro-3-oxoquinoxaline-2-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 6-Chloro-3,4-dihydro-3-oxoquinoxaline-2-carboxylate Use and application,2-Quinoxalinecarboxylicacid,6-chloro-3,4-dihydro-3-oxo-,ethyl ester technical grade,usp/ep/jp grade.

Related News: Taiwan is denying entry to Chinese nationals from Guangdong, a southern coastal province that has also been battered by the virus, and travelers who have recently visited the area. ethyl 6-chloro-3-oxo-4H-quinoxaline-2-carboxylate manufacturer If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. ethyl 6-chloro-3-oxo-4H-quinoxaline-2-carboxylate supplier Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. ethyl 6-chloro-3-oxo-4H-quinoxaline-2-carboxylate vendor At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. ethyl 6-chloro-3-oxo-4H-quinoxaline-2-carboxylate factory GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.��